ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Back to the Future: Repurposing Metformin, a Metabolically Active Drug, to Treat Mild-to-Moderate Ulcerative Colitis.Metabolites · 2026Review
- Investigating brain-derived neurotrophic factor (BDNF) changes in three main rodent models of autism spectrum disorder (ASD): a systematic review.Neurotoxicity research · 2026Review
- Different Protocols of Circadian Rhythm Disruptions Differentially Affect Locomotor Activity, and Anxiety- and Compulsive-Like Behaviors in Male vs. Female Wistar Rats along with the Significant Involvement of GSK-3β in Females.Molecular neurobiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic condition with a rising incidence linked to inflammation and oxidative stress. This disorder includes two main subtypes: ulcerative colitis (UC) and Crohn's disease (CD). Current treatment plans lack effectiveness; as a result, finding novel approaches is encouraged. Various groups of oral anti-diabetic medications are employed in clinical practice, and they have shown beneficial effects against conditions beyond diabetes mellitus (DM). This review is aimed at evaluating the hypothesis that oral anti-diabetic medications may serve as potential therapeutic agents for IBD due to their anti-inflammatory and antioxidant effects. The current study investigated the protective effects of these agents against IBD. In this review, we gathered evidence from cellular, animal, and clinical studies within the scientific databases Medline, Scopus, and Web of Science regarding the favorable impacts of anti-diabetic drugs on IBD. We explored these databases from their inception to May 2024. Studies focusing on the therapeutic impacts of these medications on diverse models of IBD were included and reviewed. Biguanides, sulfonylureas, thiazolidinediones (TZD), dipeptidyl peptidase 4 inhibitors (DPP4I), and sodium-glucose cotransporter inhibitors (SGLT2I) exhibited protective effects against IBD. These medications promoted gut microbiome balance and the function of tight junction proteins, such as zonula occludens-1 (ZO-1), occludin, and claudin. Moreover, they affected key cytokines (tumor necrosis factor (TNF), malonaldehyde (MDA)), enzymes (superoxide dismutase (SOD), glutathione peroxidase (GPX), myeloperoxidase (MPO)), and signaling pathways (nuclear factor erythroid 2-related factor (Nrf2) transcription factor/hemoxygenase 1 (HO-1), high mobility group box 1 (HMGB1)/receptor for advanced glycation end-products (RAGE)/nuclear factor kappa B (NF-κB)). Anti-diabetic medications demonstrated positive effects against IBD. However, further comprehensive clinical assessments are necessary to confirm their efficacy and safety as an adjunctive therapy for IBD.
Indexed as
Identifiers
41137867What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.